This page shows the latest Alecensa news and features for those working in and with pharma, biotech and healthcare.
NSCLC). Alecensa was shown to reduce the risk of disease recurrence by 76% compared with platinum-based chemotherapy, Roche said. ... Alecensa is already approved in over 100 countries as a first-line treatment for ALK-positive, metastatic NSCLC.
Roche has announced positive results from a late-stage study of its ALK inhibitor, Alecensa (alectinib), in early-stage lung cancer. ... Alecensa is already approved in over 100 countries as a first-line treatment for ALK-positive, metastatic NSCLC.
Lorbrena is also an important follow-up to Pfizer’s older ALK inhibitor Xalkori, which has come under pressure as it faces increasing competition from Roche’s Alecensa (alectinib) and Novartis’
Sales of Xalkori have come under pressure recently as it faces increasing pressure from Roche’s Alecensa (alectinib) and Novartis’ Zykadia (ceritinib), with both therapies having previously bested Pfizer’s ... Although Lorbrena will face extreme
In Europe, sales were down 1% thanks to the competition from biosimilars for Herception and Rituxan, but there was growth reported in the uptake of Ocrevus, Perjeta, Tecentriq, Alecensa and Hemlibra.
Alecensa (alectinib), Novartis’ Zykadia (ceritinib), and Takeda’s Alunbrig (brigatinib).
More from news
Approximately 18 fully matching, plus 24 partially matching documents found.
No results were found
OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...